Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative disorders of the central nervous system. Its news flow centers on the clinical and regulatory progress of its lead candidate, zervimesine (CT1812), an investigational oral pill in development for Alzheimer’s disease, dementia with Lewy bodies (DLB) and related conditions.
News updates from Cognition Therapeutics frequently cover milestones in its Phase 2 clinical programs. These include results and analyses from the SHINE study in mild-to-moderate Alzheimer’s disease, the SHIMMER study in mild-to-moderate DLB, and the START study in early Alzheimer’s disease. Articles describe safety and tolerability outcomes, changes in cognition and function measured by validated scales, and exploratory findings in behavioral, movement and neuropsychiatric domains.
Investors following CGTX news also see announcements about expanded access programs for zervimesine in DLB, collaborations with organizations such as the Alzheimer’s Clinical Trials Consortium, and substantial grant support from the National Institute on Aging of the National Institutes of Health. Regulatory and scientific updates, such as end-of-Phase 2 discussions with the U.S. Food and Drug Administration, Type C meeting plans, and presentations at major Alzheimer’s disease conferences, are regular features of the company’s news cycle.
In addition, Cognition Therapeutics issues press releases on financing transactions, including registered direct offerings of common stock and at-the-market equity programs, which provide context on how it funds ongoing and planned studies. For readers tracking CGTX, this news page consolidates clinical, regulatory, scientific and capital markets developments related to zervimesine and the company’s broader neurodegenerative disease pipeline.
Cognition Therapeutics (Nasdaq: CGTX) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. CEO Lisa Ricciardi and VP of Research Mary Hamby will present on May 25 at 3:30 p.m. EDT. The event will be accessible via a live and archived webcast on both the conference platform and the company's investor website. Registered investors can also schedule one-on-one meetings with management during the conference, aimed at fostering investor relations.
Cognition Therapeutics (NASDAQ: CGTX) announced the commencement of patient dosing in the second cohort of its Phase 2 SHINE study focusing on mild-to-moderate Alzheimer’s disease. The company plans to enroll patients in a dry AMD trial and the START trial in collaboration with the Alzheimer’s Clinical Trials Consortium in the second half of 2022. Financially, the company's Q1 2022 net loss was $3.8 million, or $(0.17) per share, compared to a loss of $0.9 million, or $(1.64) per share, in Q1 2021. As of March 31, 2022, cash reserves stood at $51.5 million.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced it will release its financial results for Q1 2022 on May 11, 2022. The company focuses on developing small molecule therapeutics for age-related degenerative diseases, specifically targeting Alzheimer's disease and related conditions with its lead candidate CT1812. Cognition aims to leverage its unique mechanism to regulate impaired pathways in these diseases. The announcement corrects the report date previously stated as May 10, 2022.
Cognition Therapeutics (NASDAQ: CGTX) announced it will report its financial results for Q1 2022 on May 11, 2022. The company focuses on therapies for age-related degenerative diseases in the central nervous system and retina, with its lead candidate CT1812 under investigation for conditions like Alzheimer’s and dry age-related macular degeneration. Cognition aims to innovate treatments by targeting σ-2 receptors, offering a distinct mechanism compared to current therapies.
Cognition Therapeutics (NASDAQ: CGTX) showcased a poster at the ARVO meeting, highlighting that sigma-2 receptor modulators can restore the normal functioning of retinal pigment epithelial (RPE) cells impaired by dry age-related macular degeneration (AMD).
CT1812, Cognition's lead candidate, demonstrated the ability to rescue vital functions of RPE cells in in vitro models. The company plans to initiate a Phase 2 clinical trial with CT1812 in patients with dry AMD in late 2022. Dry AMD affects around 190 million individuals globally, making it a significant health concern.
Cognition Therapeutics (NASDAQ: CGTX) announced its participation in the ARVO 2022 conference, showcasing preclinical results on sigma-2 receptor modulators that protect retinal pigmented epithelium (RPE) cells. Their lead candidate, CT1812, aims to address dry age-related macular degeneration (AMD) and a Phase 2 clinical study is planned. Dry AMD affects approximately 190 million globally, causing significant vision loss. The poster presentation is scheduled for May 3, 2022, highlighting how these modulators can normalize disrupted homeostatic processes in RPE cells.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that its management will participate in a virtual fireside chat at the B. Riley Securities’ Neuro & Ophthalmology Conference on April 27-28, 2022. The discussion will focus on advancements in their clinical programs targeting age-related diseases affecting the central nervous system and retina, particularly their lead candidate, CT1812. A webcast will be available for viewers, outlining the company's ongoing research and development efforts in Alzheimer’s disease and other conditions.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced participation in Needham & Company's 21st Annual Virtual Healthcare Conference from April 11-14, 2022. CEO Lisa Ricciardi will provide a corporate update on April 11, 2022, from 3:00 to 3:40 p.m. ET. A live and archived webcast will be available on the company's investor website. The company focuses on developing innovative drugs targeting age-related degenerative diseases affecting the central nervous system and retina, leveraging expertise in sigma-2 receptor mechanisms.
Cognition Therapeutics (NASDAQ: CGTX) reported a solid financial position after raising $52 million through an upsized IPO and securing $169 million in grant funding. The company is advancing its clinical pipeline for Alzheimer’s disease and dementia with Lewy bodies (DLB), with plans for Phase 2 studies in dry AMD and early-stage Alzheimer’s expected to begin in H2 2022. Despite a net loss of $11.7 million in 2021, Cognition's robust cash reserves of $54.7 million are projected to sustain operations through mid-2023.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) plans to announce its fourth quarter and full year financial results for 2021 on March 30, 2022, before market open. Following this release, the company will host a conference call at 8:00 a.m. ET to discuss the results and provide a business update. Participants can join via telephone or an audio webcast accessible on the company’s website. Cognition focuses on developing innovative therapeutics targeting age-related degenerative diseases.
FAQ
What is the current stock price of COGNITION THERAPEUTICS (CGTX)?
What is the market cap of COGNITION THERAPEUTICS (CGTX)?
